These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4038378)

  • 1. Erythrocyte mean corpuscular volume during cytotoxic therapy and the risk of secondary leukemia.
    de Gramont A; Rioux E; Drolet Y; Delage JM
    Cancer; 1985 Feb; 55(3):493-5. PubMed ID: 4038378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic chemotherapy-induced second primary neoplasms: clinical aspects.
    Petru E; Schmähl D
    Neoplasma; 1991; 38(2):147-55. PubMed ID: 2041574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of erythrocyte mean corpuscular volume during cytotoxic therapy as a predictive parameter of the risk of secondary leukemia in Hodgkin's disease.
    de Gramont A; Rioux E; Drolet Y; Delage JM
    Cancer Treat Rep; 1984 Dec; 68(12):1467-70. PubMed ID: 6509452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocyte mean corpuscular volume during cytotoxic therapy is a predictive parameter of secondary leukemia in Hodgkin's disease.
    de Gramont A; Louvet C; Krulik M; Smadja N; Donadio D; Laporte JP; Brissaud P; Delâge JM; Drolet Y; Rioux E
    Cancer; 1987 Jan; 59(2):301-4. PubMed ID: 3467821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in the mean corpuscular volume during the cytotoxic treatment of cancer and risk of secondary leukemia. Preliminary results].
    de Gramont A; Rioux E; Drolet Y; Barry A; Delage JM
    Sem Hop; 1984 Mar; 60(14):961-6. PubMed ID: 6326284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
    Schellong G; Riepenhausen M; Creutzig U; Ritter J; Harbott J; Mann G; Gadner H
    J Clin Oncol; 1997 Jun; 15(6):2247-53. PubMed ID: 9196137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
    Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
    Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Corticosteroid drugs: their role in oncological practice.
    Lowenthal RM; Jestrimski KW
    Med J Aust; 1986 Jan; 144(2):81-5. PubMed ID: 2417096
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas. Comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.
    Pedersen-Bjergaard J; Ersbøll J; Sørensen HM; Keiding N; Larsen SO; Philip P; Larsen MS; Schultz H; Nissen NI
    Ann Intern Med; 1985 Aug; 103(2):195-200. PubMed ID: 4014901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second cancers following antineoplastic therapy.
    Dorr FA; Coltman CA
    Curr Probl Cancer; 1985 Feb; 9(2):1-43. PubMed ID: 3888536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
    Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
    J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acute leukemia in patients treated for Hodgkin's disease].
    Boccaccio P; Rosa F; Casciaro S; D'Elia P; Romagnoli M; Ghio R
    Recenti Prog Med; 1988 Jan; 79(1):32-7. PubMed ID: 3375542
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.
    Duggan DB; Petroni GR; Johnson JL; Glick JH; Fisher RI; Connors JM; Canellos GP; Peterson BA
    J Clin Oncol; 2003 Feb; 21(4):607-14. PubMed ID: 12586796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternating MOPP and ABVD chemotherapy plus mantle-field radiation therapy in patients with massive mediastinal Hodgkin's disease.
    Longo DL; Glatstein E; Duffey PL; Young RC; Ihde DC; Bastian AW; Wilson WH; Wittes RE; Jaffe ES; Hubbard SM; DeVita VT
    J Clin Oncol; 1997 Nov; 15(11):3338-46. PubMed ID: 9363863
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of second cancers in patients treated for Hodgkin's disease.
    Boivin JF; Hutchison GB; Zauber AG; Bernstein L; Davis FG; Michel RP; Zanke B; Tan CT; Fuller LM; Mauch P
    J Natl Cancer Inst; 1995 May; 87(10):732-41. PubMed ID: 7563150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second acute leukemia and other malignancies following treatment for Hodgkin's disease.
    Valagussa P; Santoro A; Fossati-Bellani F; Banfi A; Bonadonna G
    J Clin Oncol; 1986 Jun; 4(6):830-7. PubMed ID: 3711960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP.
    Longo DL; Duffey PL; DeVita VT; Wiernik PH; Hubbard SM; Phares JC; Bastian AW; Jaffe ES; Young RC
    J Clin Oncol; 1991 Aug; 9(8):1409-20. PubMed ID: 1712836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced Hodgkin's disease.
    Straus DJ
    Hematol Oncol Clin North Am; 1989 Jun; 3(2):287-302. PubMed ID: 2473061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
    Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
    Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.